KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Capital Expenditures (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Capital Expenditures for 17 consecutive years, with $689.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 4.31% to $689.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, down 1.63% year-over-year, with the annual reading at $2.2 billion for FY2025, 1.63% down from the prior year.
  • Capital Expenditures hit $689.0 million in Q4 2025 for Abbott Laboratories, up from $496.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $755.0 million in Q4 2023 to a low of $321.0 million in Q1 2022.
  • Historically, Capital Expenditures has averaged $512.1 million across 5 years, with a median of $499.0 million in 2025.
  • Biggest five-year swings in Capital Expenditures: plummeted 35.67% in 2021 and later skyrocketed 33.77% in 2023.
  • Year by year, Capital Expenditures stood at $614.0 million in 2021, then decreased by 0.65% to $610.0 million in 2022, then increased by 23.77% to $755.0 million in 2023, then decreased by 4.64% to $720.0 million in 2024, then decreased by 4.31% to $689.0 million in 2025.
  • Business Quant data shows Capital Expenditures for ABT at $689.0 million in Q4 2025, $496.0 million in Q3 2025, and $502.0 million in Q2 2025.